Startups
NovaGo’s fully human monoclonal antibodies have the potential to become a safe and effective treatment in ophthalmology and central nervous system indications. NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent and well-studied vascular and nerve growth inhibitors.
Overview
Location
Switzerland
Employees
1-10
Total raised
$40.01M
Founded date
2015
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Mar 4, 2019 | Series A round | $10.01M |
Mentions in press and media 19
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 2, 2026 | NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury | Round led by Neurimmune and Pureos, with participation from existing and new investors; complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation. SCHLIEREN, Switzerland, ... |
| Sep 2, 2026 | NovaGo Secures USD 30 Million to Advance Proof-of-Concept Study in Acute Spinal Cord Injury | Spinal cord injury remains an area of high unmet medical need. There are currently no approved regenerative treatment options that restore lost neurological function, leaving patients and their families with limited therapeutic prospects f... |
| Sep 2, 2026 | Newlight Raises $9M in Seed Funding | Newlight, a San Francisco, CA-based clean technology and maritime aerospace startup, raised $9m in seed funding. Backers included lomarlabs, BIRD Energy, Undeterred Capital, CiRi Ventures, and Fusion VC. The company will use the capital to ... |
| Jul 4, 2025 | Araris-Team sichert sich den mit 100‘000 Euro dotierten Strüngmann Award | Das Gründerteam von Araris Biotech kann auf eine der erfolgreichsten Biotech-Firmengründungen der Schweiz in den vergangenen Jahren zurückblicken. Das 2019 aus dem Paul-Scherrer-Institut gegründete Spin-off hat eine proprietäre Linker-Payl... |
| May 30, 2025 | Schweizer Biotech-Startups dominieren europäischen Award | Das Komitee des Strüngmann Awards hat diese Woche die diesjährigen Finalistinnen und Finalisten bekanntgegeben. Vergeben wird der mit 100.000 Euro dotierte Preis am 3. Juli. In das Finale geschafft haben es: Dragan Grabulovski | Philipp Sp... |
| Dec 30, 2024 | Two Swiss biotech companies report results of Phase II clinical trials | EsoCap AG, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, announced today that the complete results of the ACESO Phase II study evaluating ESO-101 for the t... |
| May 6, 2024 | Innosuisse funded 45 Start-up innovation projects | With the Start-up innovation project, Innosuisse directly funds high potential science-based projects initiated by Swiss start-ups, giving them a financial boost to propel their market entry. The innovation projects must be based on applic... |
| Feb 9, 2024 | Leadership changes to drive these six startups forward | Serge Gander, the former CEO of CleanGreens Solutions SA, is taking over the role of CEO at bNovate, the startup that developed BactoSense, a device that automatically detects all bacteria in water through a single sampling tube in less tha... |
| Sep 23, 2020 | Gründer übergeben an erfahrene CEOs | Das Business-Software-Unternehmen bexio wurde 2013 gegründet und ist seit zwei Jahren eine Tochter der Mobiliar. Das ehemalige Start-up mit Sitz in Rapperswil SG wächst stark, bedient über 30'000 Kunden und beschäftigt derzeit über 100 Mita... |
Show more
Reviews 0
FAQ about NovaGo Therapeutics
When was NovaGo Therapeutics founded?
NovaGo Therapeutics was founded in 2015.
How much funding has NovaGo Therapeutics raised?
NovaGo Therapeutics has raised $40.01M in total across 2 funding rounds.
What funding rounds has NovaGo Therapeutics raised?
Parsers VC lists 2 funding rounds of NovaGo Therapeutics, among them a Series A round of $10.01M on Mar 4, 2019.
What has the press written about NovaGo Therapeutics?
Parsers VC has collected 19 articles mentioning NovaGo Therapeutics, among them “NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury” (Sep 2, 2026) and “NovaGo Secures USD 30 Million to Advance Proof-of-Concept Study in Acute Spinal Cord Injury” (Sep 2, 2026).
Is NovaGo Therapeutics still active?
Yes, NovaGo Therapeutics is active; its latest activity on Parsers VC dates from Sep 3, 2026.